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Deep vein thrombosis resolution is impaired in
diet-induced type 2 diabetic mice
Fatiha Bouzeghrane, PhD, Xiaochun Zhang, MD, BSc, Guylaine Gevry, BSc and Jean Raymond, MD,
Montréal, Québec, Canada
Objective: Type 2 diabetes mellitus results in a procoagulant and thrombogenic state that could predispose diabetic
individuals to develop venous thrombosis. We sought to determine whether diet-induced type 2 diabetes mellitus affects
deep venous thrombosis (DVT) resolution in a murine model.
Methods: C57Bl/6 mice were fed a low-fat or a high-fat diet (n  10) for 10 weeks, after which DVT was created in the
inferior vena cava (IVC) by a combination of low flow and endothelial damage. The IVC and thrombus were harvested
at 1 and 2 weeks. Thrombus resolution and neovascularization were investigated through transfemoral angiography
(n  10), thrombus size (n  4) and weight (n  10), and nitric oxide synthase 3 immunoquantification (n  4).
Macrophage content was assessed by CD68 immunoreactivity (n  4). The fibrinolytic system (urokinase plasminogen
activator [uPA] and plasminogen activator inhibitor-1 [PAI-1]) was analyzed by Western immunoblotting (n  6) and
immunohistochemistry (n  4). Total collagen was stained by Sirius red. Matrix metalloproteinases (MMP)-2 and MMP-9
activities were evaluated by zymography and their expressions by Western immunoblotting (n  6) and immunohistochem-
istry (n  4).
Results: Diabetic mice had significantly larger and heavier thrombi at 1 and 2 weeks (P < .05), threefold less
neovascularization (P < .05), and 35-fold increase in macrophage content (P < .01), than control mice 2 weeks after
surgery. IVC recanalization was documented in 90% of 2-week control mice and in 10% of 2-week diabetic mice (P< .01).
Increased vein wall collagen and less uPA and more PAI-1 expressions with a decreased uPA/PAI-1 ratio (31%, P< .01)
were documented at 2 weeks in diabetic mice. MMP-2 and MMP-9 activities and expressions were significantly increased
in diabetic mice at 1 and 2 weeks (P < .05) compared with control mice.
Conclusion: Diet-induced type 2 diabetes may impair DVT resolution through altered inflammatory, fibrinolytic, and
MMP responses. ( J Vasc Surg 2008;48:1575-84.)
Clinical Relevance: Little is known about the risk of venous thromboembolism in patients with type 2 diabetes mellitus,
which accounts for 95% of diabetes mellitus. Deep venous thrombosis and pulmonary embolism generating post-
thrombotic syndrome remain significant clinical problems, affecting approximately 200,000 to 300,000 patients per year.
The current obese/diabetic mouse model and the mouse model of stasis thrombus resolution provide useful approaches
for determining the effect and understanding the basic biologic mechanisms of type 2 diabetes mellitus on deep venous
thrombosis resolution, as well as serving as valuable tools for evaluating therapeutic options.In contrast to diabetic arterial complications, few and
controversial data exist on the effect of diabetes mellitus on
venous thromboembolism (VTE).1 Furthermore, the
long-held distinction between thromboembolic arterial
and VTE pathogenesis is being revised.2,3 Deep venous
thrombosis (DVT) develops in regions of relative stasis,
often in association with increased coagulability or endo-
thelial damage, which could predispose diabetic individuals
to the development of DVT.
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Vascular Surgery.doi:10.1016/j.jvs.2008.07.050A recent retrospective study showed that a higher inci-
dence of VTE (ie, DVT and pulmonary embolism), with
substantial morbidity and mortality, was associated with
diabetes mellitus4 and obesity.5 The annual incidence rate
of VTE among diabetic patients in the population was
432/100,000 individuals vs 78 in nondiabetic individuals.4
The association of diabetes mellitus with post-thrombotic
syndrome and chronic debilitating complications of DVT
was not reported. DVT in diabetes mellitus may involve, in
addition to an increased propensity for thrombosis, defec-
tive healing mechanisms that could contribute to more
severe clinical presentations such as chronic venous ob-
struction and valve destruction after DVT resolution.
Although it would be difficult to prove an increased
tendency for DVT in animal models of diabetes mellitus,
venous thrombosis models have been described6-11 that
produce a laminar thrombus similar to that formed in
human venous thrombi with a rate of resolution that cor-
relates in humans with symptomatology of post-thrombotic
syndrome.12 These models may be used to study DVT
resolution, a determinant factor on the development of
post-thrombotic syndrome. C57BL/6 mice may provide
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induced type 2 diabetes mellitus. This strain becomes
obese, hyperglycemic, and insulin resistant when fed a
high-fat diet.13-17
Vascular complications in type 2 diabetes mellitus can
partly be explained by defects of coagulation and fibrinoly-
sis that promote adhesion of platelets and monocytes along
with endothelial dysfunction, thus increasing the risk of
thrombosis and vascular injury.18,19 These multiple defects
led us to speculate that type 2 diabetes mellitus could
impair DVT resolution. The mechanisms of DVT resolu-
tion are similar to those found in wound healing and
angiogenesis, with the recruitment of inflammatory and
endothelial cells and myofibroblasts6 that contribute to
fibrinolysis,7 neovascularization,8 and fibrosis.9 Fibrinolysis
of venous thrombi is thought to be primarily mediated by
the urokinase plasminogen activator (uPA)/plasmin sys-
tem from invading monocytes.10 The matrix metallopro-
teinases (MMPs) are also involved, particularly MMP-2 and
MMP-9, which are found in abundance in venous thrombi.9
The purpose of this work was to determine whether
type 2 diabetes mellitus affects DVT resolution and neovas-
cularization, monocyte/macrophage recruitment, and col-
lagen deposition in a mouse model of stenosis with diet-
induced obesity and diabetes. Also investigated were the
expression and activity of MMP-2, MMP-9, uPA, and
plasminogen activator inhibitor-1 (PAI-1), and their distri-
bution in the thrombus and the vessel wall.
MATERIALS AND METHODS
Murine models for type 2 diabetes mellitus and
DVT. All procedures were approved by the institutional
Animal Care Committee in accordance with guidelines of
the Canadian Council on Animal Care. The study used
forty 5-week-old male C57BL/6mice weighing 20 to 22 g
(Charles River, Saint Constant, Québec, Canada). For 10
weeks, the control mice (CM, n  20) group was fed the
low-fat diet containing 10% kcal as fat (No. D12450B;
Research Diets New Brunswick, NJ), and the diabetic mice
(DM, n 20) group received a high-fat diet containing 45%
kcal from fat (No. D12451), known to induce obesity and
diabetes.13-17 The high-fat diet was continued after DVTwas
generated in the mice. Body weight and plasma glucose levels
were recorded weekly. The mice with fasting blood glucose
levels12 mmol/L were considered diabetic.13-17
Thrombosis was induced by inferior vena cava (IVC)
stenosis6 and endothelial damage.10,11 The surgical tech-
nique was repeatedly tested in a previous group of 40 mice,
and led to predictable thrombosis in approximately 98% of
mice, as previously described, where blood flow was re-
duced by 80%.6,10,11 After anesthesia with a 1% isoflurane
and oxygen mixture, the IVC was exposed through a
laparotomy, squeezed at two separate positions by a neu-
rosurgical vascular clip for 15 seconds, and stenosed with
4-0 silk ligature around a 5-0 Prolene suture (Ethicon,
Somerville, NJ) placed alongside the IVC. The 5-0 Prolene
was then removed to allow blood to continue to pass up the
vein (Fig 1).Before sacrifice at 1 week (n  20) and 2 weeks (n 
20) after thrombosis, angiography was performed on anes-
thetized mice with pentobarbital (Somnotol; MTC Phar-
maceuticals, Cambridge, Canada; 65 mg/mL; 120 mg/kg
intraperitoneally), using the same radiographic technique,
ensuring identical magnification factors from one animal to
the other. Contrast was injected in the femoral vein with a
1-mL syringe filled with radiopaque contrast medium (io-
dixanol, 320 mg/mL) and a 26 1/2-gauge needle. Digital
analysis was blindly interpreted and angiographic occlusion
defined as the absence of anterograde blood flow through
the thrombosed IVC; any antegrade opacification was suf-
ficient to label the IVC recanalized.20
At harvest, the IVC/thrombus mass (weight/length)
was calculated.8,9 Samples were snap-frozen and stored at
–80°C for biochemical study (n 6), or fixed overnight in
Zn-Tris solution, dehydrated, and paraffin-embedded for
histochemistry (n  4).
Histologic and immunohistochemical analysis, mac-
rophage content, and neovascular channel quantification.
Immunohistochemical staining was performed as de-
scribed21 using rabbit polyclonal antibodies against nitric
oxide synthetase (NOS3; 1:100) for endothelial cells;
CD68 (1:200) for monocytes/macrophages, uPA (1:200),
and PAI-1 (1:100; all from Santa Cruz Biotechnology Inc,
Santa Cruz, Calif); mouse monoclonal anti-MMP-2 and
anti-MMP-9 (1:200; Neomarkers Inc, Fremont, Calif).
Five-m deparaffinized and rehydrated sections were
blocked first with 3% hydrogen peroxide in methanol and
then with 10% normal goat serum in Tris buffer saline
Tween-20; incubated overnight with primary antibodies,
and revealed by a species-specific biotin-avidin-peroxidase
complex (Vectastain ABC KIT, Vector Laboratories, Bur-
lingame, Calif). Peroxidase activity was detected with
diaminobenzidine (Vector Laboratories). Specimens coun-
terstained with hematoxylin were visualized with a com-
puterized imaging system (Vision PE, Clemex Technolo-
gies Inc, Longueuil, Québec, Canada). Omission of
Fig 1. Mouse model of venous thrombosis. A, Endothelial dam-
age by a neurosurgery vascular clip was followed by (B) an inferior
vena cava (IVC) stenosis with a 5-0 Prolene suture (Ethicon,
Somerville, NJ) placed alongside the vein. C, The vein was ste-
nosed with the 4-0 silk ligature, and the 5-0 Prolene suture was
removed once the stenosis was done.primary antibodies served as the negative controls.
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blindly the cross-sectional area6,10 with the same image
analysis software on hematoxylin and Sirius red stained and
immunostained sections taken at defined intervals through-
out the thrombus length (10 sections/animal, n  4).
Fibrillar collagen distribution in the IVC/thrombus as-
sessed with picrosirius red staining22 was examined by
polarized light microscopy with a Zeiss Axiophot 100M
Microscopex (Carl Zeiss Microimaging, Thornwood, NY).
Collagen volume fractions (%) were evaluated by analyzing
staining intensity/pixel with Northern Eclipse image anal-
ysis software (Empix Imaging, Mississauga, Ontario, Can-
ada) in 10 to 15 fields per section around the vein wall
section (3 to 5 sections per animal, n  4). These were
summed and normalized to the cross-sectional thrombus
area, eliminating variability caused by thrombus size, and
then averaged.
CD68 cells for macrophage content and NOS3
channels for neovascularisation8 were blindly counted in
the entire IVC/thrombus section, totalled, and then in-
dexed to thrombus area to account for differences in sec-
tion technique, IVC sample location, and thrombus size.
The average calculated.
Gelatinolytic activities and Western blot analysis.
Protein samples were denatured and equal amounts of
protein extracts (20 g) in Tris-Glycine sodium dodecyl
sulfate (SDS) sample buffer were separated in a 7.5% SDS-
polyacrylamide gel electrophoresis (PAGE) containing
0.1% gelatin (Sigma, St Louis, Mo). The gel was washed in
2.5% Triton X-100 and developed for 18 hours at 37°C in
50 mmol/L Tris-hydrogen chloride (pH 7.9) and 5
mmol/L calcium chloride, stained with Coomassie blue,
and then destained in 10% acetic acid/40% methanol. Pro
and active MMP-2 andMMP-9 activities were visualized as
light bands against a dark background. Samples known to
containMMP-2 andMMP-9 (human fibrosarcoma cell line
HT1080 ATCC NOCRL-12012) were included as stan-
dards.
For analysis of the immunoreactive MMP-2, MMP-9,
uPA, and PAI-1, samples separated by 10% SDS-PAGE
were transferred onto nitrocellulose, incubated with pri-
mary antibodies, and followed by chemiluminescence
(SuperSignal West Pico, Pierce, Ill). Densitometric analysis
was assessed with AlphaImager 2000 software (Alpha In-
notech Corp, San Leandro, Calif) and normalized to milli-
grams of protein present in each sample.
Statistics. Angiographic occlusion rates were analyzed
by the Fisher exact test. Data significance (mean standard
error of the mean) was assessed by a nonparametric Mann-
Whitney test and two-way analysis of variance at P  .05
using Sigma Plot software (SPSS Inc, Chicago III). Bon-
ferroni post-tests were used to detect differences between
groups.
RESULTS
After 10 weeks of being fed a high-fat diet, the 20 DM
showed increased bodyweight from31.410.36 to 38.78
0.28 g and increased plasma glucose levels from 8.06 0.20 to 12.85  0.20 mmol/L (P  .001) compared with
CM, confirming the successful development of mild type 2
diabetes mellitus. Two of the 20 mice that received the
high-fat diet did not develop hyperglycemia (blood glucose
levels, 11.5 and 11.4 mmol/L).
Vein recanalization, thrombus resolution, and
neovascularization. As shown in representative angio-
grams, 1 week after surgery, eight of 10 CM (Fig 2,A) and
nine of 10 DM (Fig 2, B) presented occluded IVC. At 2
weeks, angiographic recanalization within the thrombus
core was documented in nine of 10 CM (Fig 2, C) com-
pared with one of 10 DM (P  .01). Fig 2, D shows
occluded IVC in 2-week DM, with only flow bypassing the
IVC occlusion through collateral circulation by way of the
perivertebral plexus.
Consistent with decreased recanalization were increases
in the DMof thrombus size (Fig 3,A) of 1.8-fold at 1 week
and 4.6-fold at 2 weeks for thrombus area (n 4, P .05)
and 1.8-fold and 2.56-fold for thrombus weight (n  10,
P  .05; Fig 3, B). Both thrombus area and weight de-
creased over 2 weeks with a higher decrease in CM than in
Fig 2. Transfemoral angiography of control and diabetic mice.
An occluded inferior vena cava was present at 1 week in both (A)
control mice and (B) diabetic mice. At 2 weeks (C) the controls
showed blood flow within the thrombus core, whereas (D) blood
flow in the diabetic mice (arrow) was mainly through side collat-
erals. Recanalization was less frequently effective in 2-week dia-
betic mice (1 of 10) compared with controls (9 of 10). *P  .01.DM; 80% vs 49% for thrombus area (P  .05) and 40% vs
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ability of DM to resolve venous thrombi. Because DM are
significantly heavier and thus their larger thrombi could
represent a less representative index of resolution, we as-
sessed thrombus neovascularization by NOS3 immuno-
staining. One week after surgery, both CM and DM
showed recanalizing channels identified as spaces lined by
NOS3 endothelial-like cells (Fig 3, C), which after quan-
tification (Fig 3,D) revealed threefold fewer NOS3 chan-
nels in 2-week DM thrombi than in CM (n  4, P  .05),
despite a NOS3 staining in the margin of the thrombus
with some NOS3 cells invading the thrombus (data not
shown).
Inflammatory response. Macrophage distribution in
IVC/thrombus cross-sections assessed by CD68 immuno-
reactivity 1 week after surgery showedmore CD68 cells in
DM (Fig 4, B) than in CM (Fig 4, A), mainly found within
the thrombus periphery. Two weeks after, macrophage
recruitment invaded the totality of DM thrombi with an
enhanced immunostaining (Fig 4, D), but no apparent
macrophage infiltration was observed in CM (Fig 4, C).
Macrophage content (Fig 4, E) showed a twofold increase
at 1 week and a 35-fold increase at 2 weeks in DM com-
pared with CM (n  4, P  .01). Moreover, thrombus
macrophage content decreased from week 1 through 2 in
CM but amplified in DM during the same period.
Fibrinolytic system. To assess possible differential
Fig 3. Both (A) thrombus size and (B) weight were significantly
greater in diabetic mice than in the controls at 1 and 2 weeks, and
both were reduced from week 1 through 2 (*P  .05). C, A
representative inferior vena cava thrombosed section is shown with
nitric oxide synthase 3 (NOS3) channels (arrow at higher mag-
nification). Scale bar: 200 m; inset, 40 m. T, Thrombus; W,
wall. D, At 2 weeks, diabetic mice had significantly fewer NOS3
channels than the controls (n 4, *P .05). Error bars represent
the standard error of the mean.plasminogen system activation after DVT in DM, uPA andPAI-1 antigen levels in IVC/thrombus segments were
determined by Western immunoblotting (Fig 5, A and B).
The amount of immunoreactive uPA corrected per milli-
gram of protein did not vary between the two groups at 1
week but was significantly reduced at 2 weeks in DM
compared with CM (18% less, n 6, P .01). In contrast,
the level of PAI-1 protein expression was increased in DM
both at 1 week (1.5-fold increase, n 6, P .01) and at 2
weeks (1.2-fold increase, n  6, P  .05) compared with
their respective CM. A uPA/PAI-1 ratio (Fig 5, C) was
calculated to yield the fibrinolytic to antifibrinolytic bal-
ance.9 At the two time points, DM had the lowest relative
amount of uPA compared with CM, with a decreased ratio
of 42% less at 1 week (P  .05) and 31% less at 2 weeks
(P  .01; n  6). Representative uPA (Fig 5, D and E) and
PAI-1 (Fig 5, F and G) immunostained IVC/thrombus
sections from CM and DM confirmed the results of the
Western immunoblotting. A strong uPA immunoreactivity
was mainly detected in the subendothelium, the media, and
the adventitia of CM (Fig 5,D) compared with DM, where
the immunolabeling was sparsely localized in the vein wall
and the thrombus periphery (Fig 4, E). Compared with
CM (Fig 5, F), DM showed more intense PAI-1 staining in
the vein wall and the thrombus periphery (Fig 5, G).
Vein wall fibrosis andMMP activity and expression.
To assess if the altered DVT resolution in the DM had any
effect on fibrosis, collagen distribution in IVC/thrombus
sections was assessed with picrosirius red staining (Fig 6).
The staining of total collagen was concentrated in the vein
wall at 1 week in both CM and DM (Fig 5, A and B). At 2
weeks a strong staining was documented in the vessel wall
and the thrombus periphery of DM (Fig 5, C). Quantifica-
tion of vein wall collagen (Fig 6, D) revealed twofold less
amount in DM at 1 week, but a significantly greater volume
fraction was found at 2 weeks (n  4, P  .05) compared
with their respective CM.
As shown in representative zymograms (Fig 7, A and B),
most MMP-2 and -9 activities are present in the pro-form.
MMP-2 activity in DM at 1 week was 1.7-fold greater than in
CM and increased 1.2-fold by 2 weeks (n 6, P .05; Fig 7,
A). As thrombus matured, MMP-2 activity decreased over
time by 20% inDMcomparedwithCM,where it increased by
12% between 1 and 2 weeks. Similarly, MMP-9 activity was
1.5-fold greater at 1 week and 1.3-fold greater at 2 weeks in
DM compared with CM (n 6, P .05).
To further confirm gelatinolytic activities, densitomet-
ric analysis of MMP-2 and MMP-9 levels by Western
immunoblotting showed significantly increased levels cor-
rected per milligram of protein in the thrombosed vein
homogenate at 1 and 2 weeks in DM compared with CM
(Fig 7, B). Two- and 1.7-fold greater protein levels of
MMP-2 and MMP-9 were present in DM at 1 week com-
pared with CM (n  6, P  .05). Over time, significantly
less MMP-2 (30%) and MMP-9 (18%) expressions were
present in the DM, while still remaining elevated and above
CM levels. Thrombosed IVC sections from DM showed
intense immunolabeling of MMP-2 and MMP-9 (Fig 7,
C), at 1 week (a and d) and 2 weeks (c and f) compared with
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endothelial cells, and adventitial fibroblasts) and cellular
components of the thrombus (macrophages, myofibro-
blasts, and endothelial-like cells).
DISCUSSION
Although type 2 diabetes mellitus has been well estab-
lished as a risk factor of arterial thrombosis, to our knowl-
edge no study has shown its potential effects on DVT
evolution and resolution. We therefore explored DVT res-
olution in C57BL/6 mice fed a high-fat diet that become
obese and hyperglycemic, as described in earlier re-
ports.13,14 Previous reports have characterized hyperinsu-
linemia, insulin resistance, endothelial dysfunction, small
increases in plasma cholesterol, no changes in circulating
free fatty acids, a decrease in plasma triglycerides, and
hypercoagulation.13-17
DVT resolution involves inflammation, fibrinolysis,
and neovascularization.6-8 All these process are affected in
DM: (1) decreased recanalization, thrombus resolution,
and neovascularization, as evidenced by unfavorable angio-
graphic evolution, larger thrombus size and weight, and
fewer NOS3 channels; (2) enhanced inflammatory re-
sponse; (3) an antifibrinolytic state; (4) increased vein wall
fibrosis; and (5) high levels of MMP-2 and MMP-9. These
findings are plausibly pertinent to impairedDVT resolution
in type 2 diabetes mellitus.
The interrelation between venous thrombosis and in-
flammation has been well documented.6,11 Monocytes are
recruited into maturing human and experimental venous
thrombi10,11 and orchestrate thrombus resolution by pro-
ducing a variety of cytokines, chemotactic and angiogenic
factors, and proteases and their inhibitors.11 Thrombus
resolution does not occur if their recruitment is restricted.6
Accumulating evidence supports a mechanistic role of in-
flammation in the pathogenesis of insulin resistance and
type 2 diabetes mellitus.23-25 Our data showed intense
macrophage invasion initially around the thrombus edge
and than entirely within DM thrombi. This temporal and
spatial pattern of monocyte movement was reported previ-
ously in non-DM.11 The increasedmacrophage numbers in
DM thrombi is probably related to impaired chemotaxis
that occurs in the setting of hyperglycemia.26
These two pathologies combined—DVT and type 2
diabetes mellitus—each associated with enhanced inflam-
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig 4. Macrophage distribution assessed by CD68 immunoreac-
tivity. CD68 cells were detected in the thrombus periphery in
both (A) control mice and (B) diabetic mice 1 week after surgery;
and at 2 weeks after thrombus induction, sparsely in (C) the
controls whereas entirely in (D) the diabetic mice. Sections are
hematoxylin-counterstained. The photomicrographs are represen-
tative of results obtained from three to five sections per mouse (n
4). Scale bar: 200 m. E, Macrophage content increased signifi-
cantly at 1 and 2weeks in the diabetic mice compared with controls
(n  4, *P  .05). Error bars represent the standard error of the
mean.
m
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bus resolution. However, increased monocyte/macro-
phage recruitment into DM thrombi was not associated
with increased thrombus resolution. The mechanisms that
Fig 5. Changes in urokinase plasminogen activator (uPA
in control mice and diabetic mice. Representative immun
uPA, more PAI-1, and a (C) decreased uPA/PAI-1 ratio
Error bars represent the standard error of the mean. D-
showed (E) less uPA labeling in the vein wall (W) and
controls. In contrast, a stronger immunostaining of PA
Sections are hematoxylin-counterstained. The photomi
sections per mouse (n  4). Scale bar: 200 m; inset: 40could explain this paradoxical finding remain unclear, andfurther research directed at understanding the role of
monocytes/macrophages in thrombus resolution in DM
may be indicated. Possible explanations may include a
decreased fibrinolytic activity of DM macrophages (down-
d plasminogen activator inhibitor-1 (PAI-1) expressions
ts of (A) uPA and (B) PAI-1 antigen levels revealed less
e diabetic mice than in the controls (n  6, *P  .05).
histologic sections, uPA and PAI-1 immunoreactivity
mbus section (T) of diabetic mice compared with (D)
as detected in (G) diabetic mice than in (F) controls.







crogrregulation of uPA/tissue plasminogen activator[tPA]) or
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of tissue factor as shown in coronary thrombosis27 and
PAI-1 after in vitro transforming growth factor- and
thrombin activation.28
Abnormalities of the fibrinolytic system are etiologic
factors in DVT, with uPA and tPA both enhanced after
DVT.7,9,10 Several mechanisms, including uPa and tPA
reduction and increased PAI-1 production, have been caus-
ally implicated in diabetic and insulin-resistant human vas-
cular disorders.18,19 PAI-1–deficient mice are protected
from high-fat diet–induced obesity and insulin resistance29
as well as the development of hepatic vein thrombosis.30
Our data showed a decrease in uPA expression and an
increase in PAI-1 expression in the thrombosed IVC of
DM. Although uPA and PAI-1 were examined in the sum
of vascular wall and thrombus and the amount of thrombus
present at 2 weeks after IVC occlusion differs significantly
between DM and CM, one could suggest that increased
PAI-1 content at 2 weeks could be the result of reduced
thrombus resolution rather than a contributor of decreased
thrombus resolution. However, immunohistochemical
analysis helped to resolve the vascular wall vs thrombus
expression of uPA and PAI-1, as shown in Fig 5, D to G,
where vascular wall (per se) expression of uPA and PAI-1
differs between groups. These variations, together with a
decreased ratio of uPA/PAI-1, demonstrated an alteration in
the fibrinolytic state in the venous bedwith a trend towards an
antifibrinolytic state. Thus, increased PAI-1 production and
reduced uPA and tPA levels (data not shown) may contribute
Fig 6. Picrosirius red staining of total collagen in (A) control
mice 1 week and (B) diabetic mice at 1 week and (C) 2 weeks after
thrombus induction. The photomicrographs are representative of
results obtained three to five sections per mouse (n 4). Scale bar:
200 m. D, Quantification of the intensity of staining per pixel in
each inferior vena cava section showed significantly less vein wall
fibrosis in diabetic mice at 1 week and a greater amount at 2 weeks
compared with controls (n 4, *P .05). Error bars represent the
standard error of the mean.to the failure of DVT resolution in DM.After DVT development, the normally thin and com-
pliant vein wall becomes thick and fibrotic.9 Type 2 diabe-
tes mellitus affects extracellular matrix turnover and regu-
lation, and thickening of the basement membrane is a
hallmark in diabetic patients.31 An increase in the extracel-
lular matrix with migration of smooth muscle cells and
endothelial alterations were observed in the intima of veins
from diabetic patients and from diabetic animal models.32
In our model, DM showed elevated vein wall fibrosis 2
weeks after DVT. However, with no measure of the vein
wall thickness, enhanced fibrosis will not necessarily con-
tribute to vein wall injury, and thus diabetic individuals do
not necessarily have a greater incidence of post-thrombotic
syndrome.
Matrix turnover is modulated by MMPs, particularly
MMP-2 and MMP-9. Among the several substrates of
these gelatinases, nonfibrillar collagens such as collagen IV,
fibronectin, laminin, and heparan sulfate represent major
components of the basement membrane.33 Besides the
numerous functions of these proteases,34MMPs are impor-
tant in the pathogenesis of thrombus formation, especially
MMP-9, which promotes coagulation cascade at the in-
flammatory lesions35 as well as in thrombus resolution after
DVT.9
In type 2 diabetic animal models and patients, MMP-2
andMMP-9 activities are altered33,36 and contribute to the
progression of thrombotic events as they regulate platelets
activation.37 At 1 and 2 weeks after DVT, DM showed an
evident up-regulation of MMP-2 and MMP-9, probably
derived from macrophages within the wall and the throm-
bus, as a response to increased inflammatory cytokines38 or
to decreased uPA activity.39 In addition, a decrease at 2
weeks was associated at the same time point with increased
collagen deposition, suggesting decreased collagenolysis
that may contribute to vein wall injury.
Although it is well established thatMMP-9 is produced
predominantly by polymorphonuclear leukocytes and mac-
rophages, macrophage content at 2 weeks after DVT did
not correlate with MMP-9 levels. This may indicate that
MMP-9 is expressed both in the vein wall (fibroblasts,
smooth muscle, and endothelial cells) and in cellular com-
ponents within the resolving thrombus (macrophages,
-actin cells, endothelial-like cells, and platelets), as
shown in Fig 7, C. Furthermore, increased MMP activity
was not accompanied with enhanced thrombus resolution,
as reported in a similar model, where increased vein wall
MMP-2 and MMP-9 activities have been associated with
smaller thrombus sizes,9 highlighting the multifaceted ac-
tions of MMPs.38
The experiments in this study are all descriptive, and no
mechanism was investigated to reverse the hyperglycemia
with hypoglycemic drugs to normalize DVT resolution and
prove the direct association between DVT and hyperglyce-
mia. In addition, because other indicators (triglyceride,
cholesterol, and insulin levels) were not evaluated, we
cannot exclude the effect of confounding factors associated
with hyperglycemia on DVT resolution. Further, the in-
traobserver and interobserver variability of measurements
Fig 7. Matrix metalloproteinase (MMP) -2 and MMP-9 activities and expressions in control and diabetic mice. A,
Significant augmentation in total MMP-2 andMMP-9 activities was noted in diabetic mice at (Left panel) 1 week and
(Right panel) 2 weeks. Representative zymograms showed most activity was in the latent form. B, Western
immunoblot analysis demonstrated increased MMP-2 and MMP-9 levels in diabetic mice 1 and 2 weeks after deep
venous thrombosis compared with controls and further indicated that MMP-2 and MMP-9 proteins were decreased in
diabetic mice from week 1 through 2 (n  6, *P  0.05). Error bars represent the standard error of the mean. C,
Representative changes in MMP-2 and MMP-9 immunoreactivities of histologic sections from (Panels b, e) control
and (Panels a, c, d and f) diabetic mice revealed more MMP-2 and MMP-9 cells in vein wall (W) and thrombus
section (T) in diabetic mice than in controls.Arrows indicate specific cell types expressingMMP-2 andMMP-9: 1, Pink
arrow for vascular smooth muscle cells; 2, green arrow for macrophages; 3, clear arrows for endothelial cells; 4, black
arrow for adventitial fibroblast. Sections are hematoxylin counterstained. The photomicrographs are representative of
results obtained from three to five sections per mouse (n  4). Scale bar: 50 m.
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yield meaningful data on the precision of these tests. More-
over, specimens were too small to assess reproducibility
within samples, while it is known that pathologic results of
vascular diseases (in carotid plaques for example) may vary
according to random sampling. These factors combine to
weaken the strength of the data. In addition, because
baseline venograms could not be performed, differences
between the extents of initial thrombosis might have been
present and could have obscured the evaluation of subse-
quent resolution.
CONCLUSION
This study used the clear differences in multiple mea-
sures of venous thrombosis to show that DVT resolution is
impaired in mice with diet-induced type 2 diabetes melli-
tus. The altered inflammatory, fibrinolytic, and MMP re-
sponses uncovered by this study have previously been de-
scribed in diabetes mellitus. This work does not improve
our understanding of these phenomena but does reveal that
in addition to their role in arterial diseases, they may affect
DVT resolution.
The mechanisms involved seem to point toward the
increased inflammatory response in diabetic mice. Hyper-
glycemia activates coagulation through its effects on plate-
let reactivity,40 whereas hyperinsulinemia inhibits fibrino-
lysis.41 Inflammation and coagulation/fibrinolysis are
tightly interrelated. In addition, hyperglycemia attenuates
the antithrombotic response to endotoxin in mice,42 prob-
ably through platelet–neutrophil interactions causing the
impairment of leukocyte function, such as migration, che-
motaxis,26 production of proinflammatory cytokines,43
and reactive oxygen species generated by advanced glyco-
sylation end products.44 Although outside the scope of this
study, it is tempting to speculate that these deficiencies may
cause the impaired DVT resolution. A pharmacologic ap-
proach, such as hypoglycemic insulin-sensitizing agents
(thiazolidinediones) or antileukocyte/platelet interaction
therapies (selectin inhibitors) may enhance DVT resolution
through their anti-inflammatory and antithrombotic prop-
erties and will serve to gain insights into the involved
mechanisms.
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